السيرة الذاتية
د. معتصم عمر طه الحوامده
CV

Prof. Dr. Mutasem Omar Taha

Department of Pharmaceutical Sciences

Faculty of Pharmacy

Jordan University

Amman - Jordan

Tel: 00962 6 5355000. ext. 23305 (Work), 00962 6 5732492(Home), 00962 777424750 (Mobile)

Fax: 00962 6 5355511 or 00962 6 5355522

Email: Mutasem@ju.edu.jo

Home page:

http://scholar.google.com/citations?user=wQF0o8gAAAAJ&hl=en

Personal Information

Marital status: Married, two daughters.
Nationality: Jordanian
Date of Birth: 5/6/1970

Academic and Educational Career

Currently

Faculty of Pharmcy – Jordan University.

Amman, Jordan

Professor of Drug Design and Medicinal Chemistry at the Department of Pharmaceutical sciences.

Head of the Drug design and Discovery unit at the Faculty of Pharmcy/ University of Jordan

29/9/2003 – 11/8/2008

Faculty of Pharmcy – Jordan University.

Amman, Jordan

Associate Professor at the Department of Pharmaceutical sciences. Teaching the Following Courses:

- Selected Topics in Drug Discovery for Ph.D. students (solo)
- Selected Topics in Drug Discovery for Ph.D. students (solo)
- Advanced Pharmaceutical Organic chemistry for M.Sc. students (solo).
- Drug Design for M.Sc. Students (solo)
- Medicinal Chemistry 1 (joint with other staff members).

- Medicinal chemistry 2 (solo).
- Advanced Pharmaceutical Organic chemistry for M.Sc. students (solo).
- Pharmaceutical applications of metal chelation (joint with other staff members).
- Selected Topics in Chromatography (Solo)
- Drug Identifiaction for M.Sc. students (joint with other staff members).
- Analytical Chemistry (joint with other staff).
- Instrumental analysis (joint with other staff memberes).

1/10/2002-
1/10/2003

Faculty of Pharmcy – Jordan University.

Amman, Jordan.

Dean Assistant at the Faculty of Pharmacy/University of Jordan

23/8/1998 –
28/9/2003

Faculty of Pharmcy – Jordan University.

Amman, Jordan.

Assistant Professor at the Department of Pharmaceutical Sciences.

1994 - 1998

Department of Chemistry - Loughborough University.

Loughborough, Leics., UK

Ph.D in synthetic organic chemistry.

Title: Some Uses of Acyliminium Ions In The Synthesis Of Isoquinolones With Potential Biological Activity. Supervisor: Prof. Harry Heaney

1993 - 1994

Department of Chemistry - Loughborough University.

Loughborough, Leics., UK

M.Sc in Medicinal Chemistry and Drug Metabolism that included taught courses and research thesis.

Distinction.

Thesis Title: New routes to acyliminium ion precursors and a synthesis of the neuvamine skeleton.

Supervisor: Prof. Harry Heaney

1987 - 1992

Faculty of Pharmacy - University of Jordan.

Amman, Jordan

BSc in Pharmaceutical Sciences.

Distinction. Grade Point Average: 87.6%.

The Islamic-Scientific College.

1987 ***Amman, Jordan***

General Secondary Education Certificate Examination. **Distinction**. Grade Point Average: 93.7 %.

Research Activities:

Areas of Interest

- Synthetic modifications of natural and synthetic biodegradable polymers towards developing new polymers of interesting pharmaceutical properties..
- Application of computer-aided molecular design techniques as aids in pharmaceutical formulation.
- Molecular modeling studies towards the discovery and design of new biologically active compounds employing novel methodologies.

Supervision of M.Sc. and Ph.D Theses

Dr. Taha supervised and Co-supervised the following M.Sc. and Ph.D. research projects:

1) The Utilization of Catalyst Software for the Discovery of New Potential Anticancer Agents. **Ihab Mustafa Almasri** (M.Sc. Thesis)**,** May 2003.
2) Synthesis and Characterization of Novel Chiral Polymer- Aluminum Composite and Its Evaluation as a New Stationary Phase for the Chromatographic Separation of Optical Isomers. **Muhammed Hashem Zweiri** (M.Sc. Thesis), November 2002.
3) The Synthesis and Microbiological Evaluation of Some Novel Derivatives of Some Natural and Synthetic Polymers. **Reema A. K. Abu Khalaf**, July 2002.
4) Synthesis of Iron-Crosslinked Benzyl and Methyl Hydroxamated Natural Polymers and its In Vitro Evaluation as Potential Matrix Material for Oral Sustained-Release Beads. **Reem H. AL-Qieshawi** (M.Sc. Thesis), December 2001.
5) Predicting Tablet Properties by the Novel Use of Molecular Modeling and Quantitative Structure Property Relationship Analysis. **Maha A. Habash** (M.Sc. Thesis), August 2001.
6) Development of *in-silico* pharmacophoric models for inhibitors of important key receptors and enzymes involved in the pathogenesis of a group of interrelated circulatory and cardiovascular diseases. **Dhia Zaki Dawoud**. (M.Sc. Thesis) December 2003.

7) The utilization of Catalyst software for the discovery of potential anti-viral agents. **Hamadeh Tarazi** (M.Sc. Thesis). December 2003.

8) Development of valid analytical technique for the analysis of the experimental neuromuscular blocker EXP150 developed at the faculty of Pharmacy/University of Jordan. **Hind Taha** (M.Sc. Thesis).

9) Preparation of taste-masking microspheres for the cephalosporin cefataxim axetil. **Abdul Hamid Odeh** (M.Sc. Thesis). 2005.

10) Generation Of An Optimal Pharmacophoric Model For Quorum Sensing Agonists And Antagonists in *Pseudomonas aeruginosa* Employing Ligand-Based Modeling Techniques And Subsequent Experimental Validation. **Waleed Zalloum** (M.Sc. Thesis). 2005

11) Modeling the Pharmacophoric Properties of the Skin Pigmentation Enzyme "Tyrosinase" followed by *in-silico* and *in-vitro* screening for new hits. **Rushdi Abu Hamdah** (M.Sc. Thesis). 2007

12) In silico modeling and search for new neurnamindase inhibitors as potential treatments for avian flu. **Areej Abu Hammad** (M.Sc. Thesis). 2006

13) Docking, CoMFA and Pharmacophor Modeling of the MurF enzyme inhibitors for the discovery of new selective anti-bacterial agents and subsequent experimental validation. **Naji Atallah** (M.Sc. Thesis). 2007

14) Discovery of new anti-diabetic GSK3–β inhibitors using ligand-based pharmacophore mopdelling and experimental validation. **Mohammad Al-Ghussein** (M.Sc. Thesis). 2007.

15) Preparation of novel matrices based on alginate-surfactant composites via ionotropic crosslinking with calcium and/or zinc and their evaluation as sustained release formulations using chlorpeniramine maleate as model drug. **Wissam Nasser** (M.Sc. Thesis). 2007

16) Discovery of dual protein tyrosine phosphatase 1B and dipeptidyl peptidase IV inhibitors via pharmacophore and QSAR analysis followed by in-silico screening and in-vitro and in-vivo experimental validation. **Ihab Al-Masri** (Ph.D. Thesis). September-2008.

17) Discovery of new cholesteryl ester transfer protein (CETP) inhibitors via ligand-based pharmacophore modelling and QSAR analysis and subsequent hit optimization. **Reema Abu Khalaf** (Ph.D. Thesis). 2009.

18) Discovery and Optimization of new β-D-Glucosidase and β-D-Galactosidase inhibitors via Pharmacophore, QSAR analysis, in-silico Screening and in-vitro Validation. **Ahmad Al-Mutanabi** (Ph.D. Thesis). 2009.

19) Discovery of new Hormone Sensitive Lipase inhibitors via Ligand-based Pharmacophore modeling and QSAR analysis followed by experimental validation. **Lina Dahabeyah** (M.Sc. Thesis). August-2008.

20) Preparation of novel matrices based on alginate-chitosan phthalate composites via ionotropic crosslinking with calcium(II) and/or zinc(II) and their evaluation as sustained release formulations using chlorpheniramine maleate as model drug. **Arwa Matter** (M.Sc. Thesis). August -2008.

21) Preparation of novel controlled-release matrices based on alginate small carboxylic acid composites via ionotropic crosslinking with calcium(II) and/or zinc(II) and their evaluation as sustained release formulations using methylene blue as model drug. **Reema Ottom** (M.Sc. Thesis). August-2008.

22) Design new NMT iniibitrs and Their Biological Evaluation. **Tareq Al-Hraznah** (M.Sc. Thesis). November-2008.

23) Discovery of new estrogen-receptor β (ERB) selective antagonists as potential anti-inflammatory agents. **Mai Taraira** (M.Sc. Thesis). 2009.

24) Discovery and Chemical Optimizatioon Of Novel Rho Kinase (Rock II) and/or ca2+/calmodulin-dependent protein kinase II (CAMKII) as potential New Anti-Hypertensive Agents. **Rand Shahin** (Ph.D. Thesis). Present

25) Discovery and optimization of new anticancer agents based on daul inhibition of heat shock protein 90 and cyclin dependent kinase-1 via ligand-based and structure-based modelling followed by in-silico screening, biological evaluation and chemical optimization. **Mahmoud A.Al-Sha'er** (Ph.D. Thesis). 2010

26) Discovery and Optimization of New Glucokinase Enzyme Activators and/or Glycogen Phosphorylase Enzyme Inhibitors as Potential Anti-Diabetic Agents. **Maha A. Habash** (Ph.D. Thesis). 2010.

27) Discovery and Optimization of new Fructose-1,6-Bisphosphatase (FBP) inhibitors as potential antidiabetic agents. **Rabab F. Tayyem** (Ph.D. Thesis). Present

28) Descovery and optimization of new β- secretase inhibitors as possible treatment for Alzheimer´s. **Afaf Al nadaf** (Ph.D. Thesis). 2009

29) Implementation of novel structure-based techniques for the discovery of new N-myristoyl transferase inhibitors as potential antifungal agents (M.Sc. Thesis). **Zeina Al-Hadidi**. 2010

30) Development of animal models for endometriosis and its use for in vivo screening (Ph.D. thesis). **Manal Abass**. 2012.

31) Synthesis and optimization of new Hormone Sensitive Lipase inhibitors as potential treatments for diabetes. **Jumanah Al-Shwabkeh** (M.Sc. thesis). 2011

32) The Use of Comparative Intramolecular Contacts Analysis to Build Valid Pharmacophore Models Against Soluble Epoxide Hydrolase Towards Development of Potential Anti-Inflamatory Agents. **Hanan Alameddin** (M.Sc. thesis). 2013.

33) Computer-Aided Molecular Design And Discovery Of New P-Glycoprotein Inhibitors Followed By In Vitro Validation On Doxorubicin Resistant Mcf7 Cell-Line. **Dana A. AlQudah** (M.Sc. thesis). 2014.

34) Development And Evaluation Of A New Docking Scoring Function Based On The Number And Quality Of Ligand – Receptor Contacts: Evaluation Against PKCθ. **Eman Eid** (M.Sc. thesis). 2014.

35) Identification of novel inhibitors of the Middle East respiratory syndrome corona virus (MERS-CoV) protease (3ClPro) by pharmacophore modeling, quantitative structure-activity relationship analysis and subsequent in-silico screening. **Manal AL-Husban** (M.Sc. Thesis). 2014.

36) Implementation Of K-Nearest Neighbor (Knn) Modeling Technology Within The Context Of Docking – Based Comparative Intermolecular Contacts Analysis (kNN-dbCICA) For The Discovery Of New Check Point Kinase 1 (Chk1) Inhibitors As Potential Anticancer Agents. **Nour Jamal Jaradat** (M.Sc. Thesis). 2014.

37) Implementation of computer-aided drug design methodology for the discovery of novel small molecule treatments for acute myloid leukemia. **Reem AbuTayeh** (Ph.D. Thesis). Present.

38) Microscopic, Histological and Physiological Studies on the Effects of Some Antioxidant Nutraceuticals on The Metronidazole Induced Infertility of Male Albino Rats. **Zeina Al-Alami** (Ph.D. Thesis) 2014.

39) Reliance on Molecular Dynamics Simulation Implemented on a Single Ligand-Protein Complex for Development of Valid Pharmacophore Model(s) for Check point Kinase 1. **Shadi Jaber** (M.Sc. Thesis) 2014.

40) The Use of ligand-based Modelling followed by *in vitro* assay for the discovery of Spleen Tyrosine Kinase inhibitors. **Safa' Amayreh** (M.Sc. Thesis) Present.

41) Optimizing the anti-tumor effect of local virgin kefir on cancer cell lines during different fermentation times, fermentation temperatures, and different proportions of kefir weight to milk volume. **Abeer Al-Nuirate** (M.Sc. Thesis) Present.

42) Implementation of new approaches for in situ covalent crosslinking of nanoparticle drug delivery systems. **Isra' Dmour** (Ph.D. Thesis) Present.

43) Search for new platelet derived growth factor beta receptor inhibitors for potential anti-angiogenesis therapy via computer-aided molecular modeling followed by bioassay. **Ruaa Alaqtash** (M.Sc. Thesis) Present.

44) Computer-Aided Drug Design and Discovery of new Fibroblast Growth Factor Receptor 1 inhibitors followed by *in vitro* assay. **Shada Alabed** (M.Sc. Thesis). Present.

45) Investigation of novel chemical methodologies for stabilization of chitosan based nanoparticles: Free radicals and metal chelation routes. **Safa Daoud** (M.Sc. Thesis). Present.

46) The use of computer-aided ligand-based modeling followed by in-vitro assay for the discovery of new epidermal growth factor receptor tyrosin Kinase Inhibitors. **Laith Al-Shdifat** (M.Sc. Thesis). Present.

Contributions in Conferences

1. New Synthetic Protocols Based on Homophthalimide Derivatives. **Taha, M.O**. ***A poster presented at the 18th RSC Perkin Division East Midlands Regional Meeting*** –UK, held on 2nd of April 1997.
2. Pharmacy education and the utilization of CAL and IT. Afifi, F.; **Taha, M.O.**, ***A poster presented at the 18th International Congress of Biochemistry and Molecular Biology***, Beyond the Genom, 16-20 July 2000 – International Conference Center, Brimingham, UK.

3. Synthesis of Iron-Crosslinked Hydroxamated Alginic Acidand its In vitro Evaluation as a Potential Material for Oral Sustained –Release Beads. **Taha, M.O.** and Aiedeh, K. ***A poster presented at the 2nd International Conference of the Faculty of Pharmacy***, October, 2001, Amman-Jordan.

4. Synthesis of Iron-Crosslinked Chitosan Succinate and Iron-Crosslinked Hydroxamated Chitosan Succinate and their in vitro Evaluation as Potential Matrix Materials for Oral Theophylline Sustained-Release Beads. Aiedeh, K. and **Taha, M.O.** A poster presented at the 2nd ***International Conference of the Faculty of Pharmacy***, October, 2001, Amman-Jordan.

5. A symposium entitled "Advanced Computer Aided Drug Discovery Techniques Adopted In The Faculty Of Pharmacy / The University Of Jordan" was held in Jordan University on the 28th of August-2003 in which Dr. Taha and his group presented their research results in the area of computer aided drug design:

6. Combining Molecular Docking Simulations And Comparative Field Analysis To Probe Drug-B-Cyclodextrin Complexes. M. B. Zughul, **M. O. Taha**, M. M, Al Omari, M. I. El-Barghouthy, A. A. Abdo, K. Al Sou'od, A. A. Badwan. ***Proceedings of the XIII International Cyclodextrins Symposium. Turin, Itally***, May 2006.

7. Homology Modelling of the Extracellular Domain of GABAc receptors using Homology Modelling, Docking/Scoring and 3D QSAR Analysis. Heba R. Abdel Haleem, **Mutasem Taha**, David Hibbs, Jane Hanrahan, Mary Chebib. ***Proceedings of the International Conference of the Asia/Pacific Molecular Graphics and Modelling Society, Curtin University of Technology, Perth, Australia***, April, 2006.

Publications

1) A Concise Route To Tetrahydrophenanethridinones and Functionalised Isoquinolones. Heaney. H.; **Taha, M.O**., ***Synlett***, 1996, 820 - 822.

2) The oxidation of homophthalimide derivatives by dioxygen in alkaline media and cleavage-cyclisation reactions. Heaney, H.; **Taha, M.O**.; Slawin, A.M.Z., ***Tetrahedron Lett.***, 1997, 38, 3051-3054.

3) The Bis(homoallylic) Stabilisation of an Acyliminium Ion and Reactions with Nucleophiles. Heaney. H.; **Taha, M.O.**, ***Tetrahedron Lett.***, 1998, 39, 3341-3344.

4) *N*-Acyliminium ion cyclisation *versus* rearrangement. The synthesis of 13,13-dimethylberberines and 3,4-dimethylisoquinolin-1-ones, Heaney, H.; **Taha, M.O**., ***Tetrahedron Letters***, 2000, **41**, 1993-1996.

5) The oxidation of 3-alkylhomophthalimide derivatives by dioxygen in alkaline media and Bischler-Napieralski reactions of cleavage-cyclization products. Heaney, Harry; **Taha, Mutasem O**; ***Arkivoc***, 2000, 1(3), 335-351.

6) Synthesis of Chitosan Succinate and Chitosan phthalate and Their Evaluation as Suggested Matrices in Orally administered, Colon-Specific Drug Delivery Systems. Aiedeh, K.; **Taha, M.O**., ***Archiv Der Pharmazie***, 1999, 332, 103-107.

7) Synthesis of Chitosan Triethylene Glycol Phthalate and its Evaluation as a Binder in Wet granulation Procedures. Aiedeh, K; **Taha, M.O.**, ***Die Pharmazie***. 1999, 54, 614-619.

8) An Investigation on the Suitability of Chitosan-Triethyleneglycol-Phthalate as a Matrix in Prolonged-Release, Orally Administered, Chlorpheniramine Maleate Granules. **Taha, M.O.** and Aiedeh, K, Amro, B., ***STP Pharma Sciences*** 2000. **10**,395-400.

9) Synthesis of Iron-Crosslinked Hydroxamated Alginic Acid and its *in vitro* Evaluation as a Potential Matrix Material for Oral Sustained-Release Beads. **Taha, M.O**. and Aiedeh, K., ***Die Pharmazie***, 2000, **55**, 663-667.

10) Spectrophotometric and Conductimetric Study of the Complexation of Ranitidine to Fe^{+2}, Fe^{+3}, Al^{+3}, Mg^{+2}, Cu^{+2}, Ni^{+2} and Pb^{+2} Metal ion: Pharmaceutical Implications, Hamdan, I.; **Taha, MO**., ***Scientia Pharmazeutica*** (Sci. Pharm.) 2000, 68, 357-367.

11) Synthesis of Iron-Crosslinked Chitosan Succinate and Iron-Crosslinked Hydroxamated Chitosan Succinate and their in vitro Evaluation as Potential Matrix Materials for Oral Theophylline Sustained-Release Beads, Aiedeh, K.; **Taha, M.O.** ***European Journal of Pharmaceutical Sciences***, 2001, Vol 13/2, pp 159-168.

12) Aiedeh, K.; **Taha, M. O**.; Sweileh, B. Testosterone-succinate-dextran and testosterone-succinate-polyvinyl alcohol conjugates: Synthesis and testosterone release in plasma. ***Acta Technologiae et Legis Medicamenti***, 2001, 12(3), 267-281.

13) Amro, B. I.; **Taha, M. O**.; Aiedeh, K. Evaluation of chitosan-triethyleneglycol-phthalate as a potential matrix for chlorpheniramine maleate controlled-release oral tablets. ***Acta Technologiae et Legis Medicamenti*** 2001, 12(3), 239-252.

14) Development of QSPR models for Pseudoternary Microemulsions Formulated with Nonionic Surfactants and Cosurfactants: Application of Data Mining and Molecular Modeling. **M. O. Taha;** M. Al-Ghazawi; H. Abu-Amara; E. Khalil. ***European Journal of Pharmaceutical Sciences*** 2002, 15(5), 461-478

15) In-vitro Alpha-Amylase Inhibitory Effects of Some Clinically Used Drugs. Hamdan, I.; Affifi, F.; **Taha, M.O**.; ***Die Pharmazie***, 2004, 59 (10), 799-801.

16) Investigation of the Active Constituents of Portulaca Oleraceae L. (Portulacaceae) Growing in Jordan. Rashed, A. N.; Afifi, F. U.; Shaedah, M.; **Taha, M. O**.; ***Pakistan Journal of Pharmaceutical Sciences***, 2004, 17(1), 37-46.

17) Evaluation of Chitosan-Succinate and Chitosan-Phthalate as Enteric Coating Polymers for Diclofenac Sodium Tablets. Aiedeh, K.; **Taha, M. O.**; Al-Khatib, H. ***Drug Delivery Science and Technology (STP Pharma Sciences)***, 2005, 15 (3), 207-211.

18) Ligand-Based Assessment of Factor Xa Binding Site Flexibility via Elaborate Pharmacophore Exploration and Genetic Algorithm-Based QSAR Modeling. **Taha, Mutasem O**.; Qandil, Amjad M.; Zaki, Dhia D.; Murad A. AlDamen. ***European Journal of Medicinal Chemistry***, 2005, 40(7), 701-727.

19) Synthesis of Zinc-Crosslinked Thiolated Alginic acid Beads and their In Vitro Evaluation as Potential Enteric Delivery System Utilizing Folic Acid as Model Drug. **Mutasem O. Taha**, Khalid M. Aiedeh, Yusef Al-Hiari and Hatim Al-Khatib. ***Die Pharmazie***. 2005, 60, 736-742.

20) QSPR Modeling of Pseudoternary Microemulsions Formulated Employing Lecithin Surfactants: Application of Data Mining, Molecular and Statistical Modeling. **Mutasem O. Taha**, Heba Abdel-Halim, Mutasim Al-Ghazawi, Enam Khalil. ***International Journal of Pharmaceutics***. 2005, 295, 135-155.

21) Application of novel chitosan derivatives in the dissolution enhancement of a poorly water soluble drug using spray drying technique. Khalid M. Aiedeh, Hatim Al-Khatib, **Mutasem O. Taha**, Nizar Al-Zo'by, ***Die Pharmazie***. 2006, 61, 306-311.

22) Effects of variable docking conditions and scoring functions on the qualities of protein aligned CoMFA models constructed from diverse h-PTP 1B inhibitors. **Mutasem O. Taha*,** Murad AlDhamin. ***Journal of Medicinal Chemistry***. 2005, 48, 8016-8034.

23) Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation. Bustanji, Y.; **Taha, M. O*.**; Yousef, M.; Bakri, AG. ***Journal of Enzyme Inhibition and Medicinal Chemistry*.** 2006, 21,163-71.

24) Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening. **Mutasem O. Taha*,** Amal G. Al-Bakri and Waleed A. Zalloum ***Bioorganic & Medicinal Chemistry Letters***, 2006,16, 5902-5906.

25) Synthesis and in vitro behavior of iron-crosslinked N-methyl and N-benzyl hydroxamated derivatives of alginic acid as controlled release carriers. Hatim S. AlKhatib, **Mutasem O. Taha**, Khaled M. Aiedeh, Yasser Bustanji and Bassam Sweileh. ***European Polymer Journal,*** 2006, 42, 2464-2474.

26) Discovery of New Potent Human Protein Tyrosine Phosphatase Inhibitors Via Pharmacophore and QSAR Analysis Followed by In-Silico Screening. **Mutasem O. Taha***, Yasser Bustanji, Amal G. Al-Bakri, Al-Motassem Yousef, Waleed A. Zalloum, Ihab M. Al-Masri and Naji Atallah. ***Journal of Molecular Graphics and Modelling***, 25 (2007) 870–884

27) Effect of Increasing Concentrations of Quinine on the Volatile compounds in Cultured Tissues of Iris atrofusca Baker and Iris petrana Dinsmore. Ahmad H. Al-Ghabesh, Dhia S. Hassawi, **Mutasem O. Taha**, Fatma U. Afifi**.** ***Biotechnology,*** 25 (2007) 218–224.

28) Effect of Ionic Crosslinking on the Drug Release Properties of Chitosan Diacetate Matrices. Khaled M. Aiedeh, **Mutasem O. Taha**, Yusuf Al-Hiari, Yasser Bustanji, Hatim S. Alkhatib**.** ***Journal of Pharmaceutical Sciences,*** 2007, 96 (1), 38-43.

29) Combining Docking, Scoring and Molecular Field Analyses To Probe Influenza Neuraminidase-Ligand Interactions. Areej M. Abu Hammad, Fatima Afifi, **Mutasem O. Taha*.** *Journal of Molecular Graphics and Modelling***, 2007. 26, 443–456.**

30) Sodium Lauryl Sulfate Impedes Drug Release From Zinc-Crosslinked Alginate Beads: Switching From Enteric Coating Release Into Biphasic Profiles. **Mutasem O. Taha***, Wissam Nasser, Adel Ardakani, Hatim S. AlKhatib. ***International Journal of Pharmaceutics***, 2008, 350, 291-300

31) Discovery of New MurF Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by in-silico screening. **Mutasem O. Taha***, Naji Atallah, Amal G. Al-Bakri, Catherine Paradis-Bleau, Hiba Zalloum , Khaled Younis and Roger C. Levesque. ***Bioorganic and Medicinal Chemistry***. 2008, 16, 1218-1235.

32) Olanzapine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation. Mohammad K. Mohammad, Ihab M. Al-Masri, **Mutasem O Taha**, Mohamed A. S. Al-Ghussein, Hatim S. AlKhatib, Samer Najjar, Yasser Bustanji. ***European Journal of Pharmacology***, 2008, 584, 185–191.

33) Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis and In Silico Screening Reveal Potent Glycogen Synthase Kinase-3β Inhibitory Activities for Cimetidine, Hydroxychloroquine and Gemifloxacin. **Mutasem O. Taha***, Yasser Bustanji, Mohamed A.S. Al-Ghussein, Mohammad Mohammad, Hiba Zalloum, Ihab M. Al-Masri, Naji Atallah. ***Journal of Medicinal Chemistry***, 2008, 51, 2062–2077.

34) Development of Predictive In Silico Model for Cyclosporine- and Aureobasidin-Based P-Glycoprotein Inhibitors Employing Receptor Surface Analysis. Hiba M. Zalloum, **Mutasem O. Taha***, ***Journal of molecular graphics and Modelling***, 2008, 27, 439–451

35) Combining Ligand-Based Pharmacophore Modeling, QSAR Analysis and In -Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors. **Mutasem O. Taha***, Lina A. Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suheer Saleh. ***Journal of Medicinal Chemistry***, 2008, 51, 6478–6494.

36) Discovery of New DPP IV Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by in-silico screening. Ihab M. Al-Masri, Mohammad K. Mohammad, **Mutasem O. Taha***. ***ChemMedChem***, 2008, 3, (11), 1763-1779

37) **Book Chapter**: Ethnopharmacology as an emergent discipline: From empirical knowledge to drug discovery. Talal Aburjai, Rabab Tayyem and **Mutasem Taha**. ISBN 978-81-308-0213-8.

38) Inhibition of Glycogen Synthase Kinase by Curcumin: Investigation by Simulated Molecular Docking and Subsequent in vitro/in vivo evaluation. Yasser Bustanji, **Mutasem O.Taha**, Ihab M. Almasri, Mohamed A.S. Al-Ghussein, Mohammad, K. Mohammad, and Hatim S. AlKhatib, ***Journal of Enzyme Inhibition and Medicinal Chemistry***. 2009, 771 – 778.

39) Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. Ihab M. Al-masri, Mohammad K. Mohammad, **Mutasem O. Taha**. Journal of Enzyme Inhibition and Medicinal Chemistry. 2009, 24(5), 1061-1066.

40) Phenytoin Enhances Collagenization in Excision Wounds and Tensile Strength in Incision Wounds. Eyad Qunaibi, Ahmad Disi, **Mutasem Taha**. ***Pharmazie***, 2009, 64, 584-586

41) In Silico Screening for Non-Nucleoside HIV-1 Reverse Transcriptase Using ADMET-filtration and High Throughput Docking. Yasser Bustanji, **Mutasem O. Taha**, Ihab M. Al-masri. ***Chemical Biology & Drug Design***, 2009; 74: 258–265

42) Homology modeling of MCH1 receptor and validation by docking/scoring and protein-aligned CoMFA. Areej Abu-Hammad, Waleed A. Zalloum, Hiba Zalloum, Ghassan Abu-Sheikha, **Mutasem O. Taha***. ***European Journal of Medicinal Chemistry,*** 2009, 44, 2583–2596.

43) Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B. Yasser Bustanji, **Mutasem O. Taha**, Ihab Mustafa. Almasri, Mohammad Khalil. Mohammad***. Biological and Pharmaceutical Bulletin***, 2009,32 (4), 640-645.

44) Pharmacophore modelling, Quantitative Structure-Activity Relationship Analysis and Shape-Complemented In-Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors. Areej M. Abu Hammad, **Mutasem O. Taha*.** ***Journal of Chemical Information and Modeling.*** 2009, 49, 978–996.

45) Pharmacophore and QSAR Modeling of Estrogen Receptor β Ligands and Subsequent Validation and In Silico Search for New Hits. **Mutasem O. Taha,*** Mai Tarairah, Hiba Zalloum, Ghassan Abu-Sheikha. ***Journal of molecular graphics and Modelling***, 2010, 28 383–400

46) Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Reema Abu Khalaf, Ghassan

Abu Sheikha, Yasser Bustanji, **Mutasem O. Taha.*** ***European Journal of Medicinal Chemistry***. 2010, 45, 1598–1617.

47) Elaborate Ligand-Based Pharmacophore Exploration and QSAR Analysis Guide the Synthesis of Novel Pyridinium-based Potent β-Secretase Inhibitory Leads. Afaf Al-Nadaf, Ghassan Abu Sheikha, **Mutasem O. Taha*** ***Bioorganic & Medicinal Chemistry***, 2010, 18 3088–3115

48) Discovery of New β-D-Glucosidase Inhibitors via Pharmacophore Modeling and QSAR Analysis Followed by In Silico Screening. Reema Abu Khalaf, Ahmed Mutanabbi Abdula, Mohammad S. Mubarak, **Mutasem O. Taha***, ***Journal of Molecular Modeling***, 2011, 17, 443–464.

49) Discovery of Novel CDK1 Inhibitors by Combining Pharmacophore Modeling, QSAR Analysis and In Silico Screening followed by In Vitro Bioassay. Mahmoud A.Al-Sha'er, **Mutasem O. Taha***, ***European Journal of Medicinal Chemistry***. 2010, 45, 4316-4330.

50) Discovery of New β-D-Galactosidase Inhibitors via Pharmacophore Modeling and QSAR Analysis Followed by In Silico Screening. Ahmed Mutanabbi Abdula, Reema Abu Khalaf, Mohammad S. Mubarak, **Mutasem O. Taha***, ***Journal of Computational Chemistry***, 2011, 32, 463-482.

51) Thujone Corrects Cholesterol and Triglyceride Profiles in Diabetic Rat Model, Nour W. Al – Haj Baddar, Ahmad M. Disi, Talal A. Aburjai, **Mutasem O. Taha**. ***Natural Products Research***, 2011, 25, 1180–1184

52) Elaborate Ligand-Based Modeling Reveal New Nanomolar Heat Shock Protein 90a Inhibitors, Mahmoud A.Al-Sha'er, **Mutasem O. Taha***, ***Journal of Chemical Information and Modeling***, 2010, 50, 1706-1723.

53) Rational Exploration of New Pyridinium-Based Hsp90α inhibitors Tailored To Thiamine Structure. Mahmoud A.Al-Sha'er, **Mutasem O. Taha*** ***Medicinal Chemistry Research***, 2012, 21, 487-510.

54) Some Sulfonamide Drugs Inhibit ATPase Activity of Heat Shock Protein 90: Investigation by Docking Simulation and Experimental Validation. Ghassan Abu-Sheikha, Mahmoud Al-Sha'er, **Mutasem O. Taha*** ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 2011, 26, 603-609.

55) Preparation of Polyester-Based Metal-Cross Linked Polymeric Composites as Novel Materials Resistant to Bacterial Adhesion and Biofilm Formation. Suhair Saleh, Bassam Sweileh, Sami O. Taha, Ruhaifa Mahmoud, **Mutasem O. Taha*.** ***Molecules*** 2011, 16, 933-950.

56) Discovery of New Renin Inhibitory Leads via Sequential Pharmacophore Modeling, QSAR Analysis, In Silico Screening and In Vitro Evaluation. Afaf H. Al-Nadaf and **Mutasem O. Taha***. ***Journal of Molecular Graphics and Modelling***, 2011, 29, 843–864.

57) Docking-Based Comparative Intermolecular Contacts Analysis as New 3D QSAR Concept for Validating Docking Studies and In Silico screening: NMT and GP Inhibitors as Case Studies. **Mutasem O. Taha***, Maha Habash, Zeina Al-Hadidi, Amal Al-Bakri, Khaled Younis, Suhaib Sisan. ***Journal of Chemical Information and Modeling***, 2011, 51, 647–669.

58) Ethosuximide and Phenobarbital Promote Wound Healing via Enhancing Collagenization, Dema M. Ajwee, Ahmad M. Disi, Eyad A. Qunaibi, **Mutasem O. Taha***, ***Chemical Biology & Drug Design***, 2011, 79, 137-142.

59) Discovery of New Nanomolar Peroxisome Proliferator-Activated Receptor <gamma> Activators via Elaborate Ligand-Based Modeling Belal O. Al-Najjar, Habibah A. Wahab*, Alexander Chong Shu-Chie, Nur Adelina Ahmad Noruddin, **Mutasem O. Taha*** ***European Journal of Medicinal Chemistry***. 2011, 46, 2513-2529.

60) Preparation of Silver- and Zinc-doped Mullite-based Ceramics Showing Anti Bacterial Biofilm Properties Suhair Saleh, **Mutasem O. Taha**, Randa N. Haddadin, Duá Marzooqa, Hamdallah Hodali. ***Molecules*** 2011, 16, 2862-2870.

61) Discovery of New Anti Fungal Leads via Pharmacophore Modeling and QSAR Analysis of Fungal N-Myristoyl Transferase Inhibitors followed by In Silico Screening. **Mutasem O. Taha***, Tariq Al-Haraznah, Reema Abu Khalaf, Amjad M. Qandil, Hiba Zalloum, Amal G. Al-Bakri, Ghassan Abu Sheikha. ***Chemical Biology & Drug Design***, 2011, 78, 391–407.

62) Ligand-Based Modelling followed by Synthetic Exploration Unveil Novel Glycogen Phosphorylase Inhibitory Leads. Maha Habash, **Mutasem O. Taha***. ***Bioorganic & Medicinal Chemistry***, 2011, 19, 4746-4771.

63) Elaborate Ligand-Based Modeling and Subsequent Synthetic Exploration Unveil New Nanomolar Ca2+/Calmodulin-Dependent Protein Kinase II Inhibitory Leads. Rand Shahin and **Mutasem O. Taha***. ***Bioorganic & Medicinal Chemistry***, 2012, 20, 377–400.

64) Elaborate Ligand-Based Modeling Reveal New Submicromolar Rho Kinase Inhibitors. Rand Shahin, Saja Al Qutaishat, **Mutasem O. Taha*.** ***Journal Of Computer-Aided Molecular Design***, 2012, 26, 249-266.

65) Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors. Reema Abu Khalaf, Ghassan Abu Sheikha, Mahmoud Al-Sha'er, Ghadeer Albadawi and **Mutasem Taha**, ***Medicinal Chemistry Research***, 2012, 21:3669–3680.

66) Effect of particle morphology and pore size on the release kinetics of ephedrine from mesoporous MCM-41 materials. Dua'a M. Marzouqa, Mohammad B. Zughul, **Mutasem O. Taha**, Hamdallah A. Hodali. ***Journal of Porous Materials***, 2011, 19, 825–833.

67) Formulation and Characterization of IPM/Water/Nonionic-Ionic Surfactant Microemulsions. Enam Khalil*, Shorouq T. Al-Sotari, **Mutasem O. Taha**. ***Journal of Chemistry and Chemical Engineering***, 2012, 6, 187-198.

68) Pharmacophore and QSAR Modeling of Endotholial Nitric Oxide Synthase Inhibitors and Subsequent Validation and In Silico Search for New Hits. Ghadeer A. R. Y. Suaifan, Heba A. N. Al-Ejal, **Mutasem O. Taha***. ***Jordan Journal Of Pharmaceutical Sciences***. 2012, 5, 220-243.

69) Extensive Ligand-Based Modeling And In Silico Screening Reveal Nanomolar Inducible Nitric Oxide Synthase (iNOS) Inhibitors**.** Ghadeer Suaifan, Mayyada Shehadehh, Hebah Al-Ijel, **Mutasem Taha*.** ***Journal of Molecular Graphics and Modelling***, 2012, 37, 1-26.

70) **<u>Edited Book and Book Chapter</u>:** Virtual Screening, Mutasem Taha (Editor), 2012, ISBN 978-953-51-0308-0

71) Synthesis and biological activity assays of some new N1-(flavon-7-yl) amidrazone derivatives and related congeners. Marwa N. Abu-Aisheh, Mohammad S. Mustafa, Mustafa M. El-Abadelah, Randa G. Naffa, Said I. Ismail, Malek A. Zihlif, **Mutasem O. Taha**, Mohammad S. Mubarak* ***European Journal of Medicinal Chemistry***, 2012, 54, 65-74

72) Application of Docking-Based Comparative Intermolecular Contacts Analysis for Validating Hsp90α Docking Studies and Subsequent In Silico screening for Inhibitors. Mahmoud A.Al-Sha'er, **Mutasem O. Taha*** , ***Journal of Molecular Modelling***, 2012, 18, 4843–4863

73) Famotidine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation. Mohammad Mohammad, Ihab M. Al-Masri, Ala Issa1, Mohamed A.S. Al-Ghussein, Mohammad Fararjeh, Hatim Alkhatib, **Mutasem O. Taha**, Yasser Bustanji. ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 2013, 28(4), 690-4.

74) Ligand-Based Pharmacophore Exploration and QSAR Analysis of Transition State Analogues followed by In Silico Screening Guide the Discovery of New Sub-Micromolar <beta>-Secreatase Inhibitors. Afaf Al-Nadaf**, Mutasem O. Taha***. ***Medicinal Chemistry Research***, 2013, 22, 1979–1997.

75) β-Caryophyllene Causes Regression of Endometrial Implants in a Rat Model of Endometriosis without Affecting Fertility. Manal A. Abbas, **Mutasem O. Taha**, Malek A. Zihlif, Ahmad M. Disi. ***European Journal of Pharmacology***, 2013, 702, 12–19.

76) Evaluation of Naproxen and Cromolyn Activities against Cancer Cells Viability, Proliferation, Apoptosis, p53 and Gene Expression of Survivin and Caspase-3. Tarek M. K. Motawi, Yasser Bustanji, Shohda EL-Maraghy, **Mutasem O. Taha** and Mohamed A. S. Al Ghussein. ***Journal of Enzyme Inhibition and Medicinal Chemistry***, 2014, 29, 153–161.

77) Pharmacophore Modeling, Homology Modeling, and in silico Screening Reveal Mammalian Target of Rapamycin Inhibitory Activities for Sotalol, Glyburide, Metipranolol, Sulfamethizole, Glipizide, and Pioglitazone. Mohammad A. Khanfar, Majed M. AbuKhader, Saja Alqtaishat, **Mutasem O. Taha**,* ***Journal of Molecular Graphics and Modelling***, 2013, 42, 39–49.

78. Elaborate Ligand-Based Modeling Reveal New Migration Inhibitory Factor Inhibitors, Mahmoud A.Al-Sha'er, Sonya VanPatten, Yousef Al-Abed, **Mutasem O. Taha*** ***Journal of Molecular Graphics and Modelling***, 2013, 42, 104-114.

79. Design, Synthesis and Structure-Activity Relationship of New HSL Inhibitors Guided by Pharmacophore Models. Jumana D. Al-Shawabkeh, Afaf H. Al-Nadaf, Lina A. Dahabiyeh, **Mutasem O. Taha***, ***Medicincal Chemistry Research***, 2014, 23 (1), 127-145.

80. Regression of endometrial Implants treated with vitamin D3 in a rat model of endometriosis. Manal A. Abbas, **Mutasem O. Taha**, Ahmad M. Disi, Maha Shomaf, ***European Journal of Pharmacology***, 2013, 5, 715, 72-75.

81. Naproxen and Cromolyn as New Glycogen Synthase Kinase 3β Inhibitors Investigated by Docking Simulation and subsequent In vitro/ In vivo Biochemical Evaluation Helps for Diabetes and Obesity. Tarek M. K. Motawi, Yasser Bustanji, Shohda EL-Maraghy, **Mutasem O. Taha**, Mohamed A. S. Al Ghussein. ***Journal of Biochemical and Molecular Toxicology***. 2013, 27, 425-436.

82. Sunitinib as an Anti-Endometriotic Agent. Manal A. Abbas, Ahmad M. Disi, **Mutasem O. Taha** ***European Journal of Pharmaceutical Sciences***. 2013, 16, 732–736.

83. Synthesis of A Novel Chitosan-Based Polymer Employing Ugi Reaction And Application As A Matrix For Controlled Drug Delivery. Ardakani A, Al-Zoubi N, Sakhnini N, **Taha MO***. ***Jordan Journal of Pharmaceutical Sciences.*** 2013**,** 6, 2, 233-241.

84. New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study. Ihab M Almasri, **Mutasem O Taha**, Mohammad K Mohammad. ***Archives of pharmacal research,*** 2013, 36 (11), 1326-1337.

85. Synthesis and characterization of new derivatives of alginic acid and evaluation of their iron (III)-crosslinked beads as potential controlled release matrices. SR Abulateefeh, MA Khanfar, RZ Al Bakain, **MO Taha***. ***Pharmaceutical development and technology***, 2014, 19 (7), 856-867

86. Preparation and in vitro characterization of glibenclamide-loaded alginate hexyl-amide beads: a novel drug delivery system to improve the dissolution rate. A Khames, AH Abdelazeem, M Habash, **MO Taha**. ***Pharmaceutical development and technology***, 2014, 19 (7), 881-890

87. Elaborate Ligand-Based Modeling Coupled with Multiple Linear Regression and K Nearest Neighbor QSAR Analyses Unveiled New Nanomolar mTOR Inhibitors. MA Khanfar, **MO Taha***, ***Journal of chemical information and modeling***, 2013, 53 (10), 2587–2612.

88. Design, Synthesis and Biological Evaluation of N4-Sulfonamido-Succinamic, Phthalamic, Acrylic and Benzoyl Acetic Acid Derivatives as Potential DPP IV Inhibitors R Abu Khalaf, G Abu Sheikha, M Al-Sha'er, **MO Taha**. ***Open Medicinal Chemistry Journal***, 2013, 7, 39-48

89. Preparation of novel ionotropically crosslinked beads based on alginate-terephthalic acid composites as potential controlled release matrices. Reema Al-Otoum, Samer R. Abulateefeh, **Mutasem O. Taha***. ***Die Pharmazie***, 2014, 69(1), 10-18

90. Discovery of Novel Urokinase Plasminogen Activator (uPA) Inhibitors Using Ligand-Based Modelling and Virtual Screening followed by In Vitro Analysis. Mahmoud A.Al-Sha'er, Mohammad A. Khanfar, **Mutasem O. Taha*.** ***Journal of Molecular modeling,*** 2014, 20(1), 2080-2095.

91. Synthesis and Antitumor Activities of Some New N1-(Flavon-6-yl)amidrazone Derivatives. Almeqdad Y. Habashneh, Mustafa M. El-Abadelah, Malek A. Zihlif, Amer Imraish, and **Mutasem O. Taha**. ***Archiv Der Pharmazie***. 2014, 347, 1–8.

92. Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors. Maha Habash, Ahmed H. Abdelazeem, **Mutasem O.Taha*.** ***Medicinal Chemistry Research***. 2014, 23, 3876–3896.

93. The Use of Docking-Based Comparative Intermolecular Contacts Analysis to Identify Optimal Docking Conditions within Glucokinase and to Discover of New GK Activators. **Mutasem O. Taha***, Maha Habash, Mohammad A. Khanfar. ***Journal of Computer-Aided Molecular Design***, 2014, 28, 509–54.

94. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors. S Abuhamdah, M Habash, **MO Taha***. ***Journal of computer-aided molecular design*** 2013, 27, 1075-1092.

95. Enhanced drug encapsulation and extended release profiles of calcium-alginate nanoparticles by using tannic acid as a bridging cross-linking agent. SR Abulateefeh, **MO Taha**. ***Journal of microencapsulation***, 2014, In Press.

96. Haloperidol inhibits Memapsin 2: Innovation by docking simulation and in vitro assay. AH Al-Nadaf, **MO Taha**, HK Aldal'in, ***Pakistan Journal of Pharmaceutical Sciences***, 2015, 28, 139-146.

97. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. **MO Taha**, MA Al-Sha'er, MA Khanfar, AH Al-Nadaf. ***European journal of medicinal chemistry*** 2014, 84, 454-465.

98. Ligand-based modelling Followed by in Vitro Bioassay Yielded New Potent Glucokinase Activators. **MO Taha***, M Habash, MH Ma'mon, AH Abdelazeem, A Qandil. ***Journal of Molecular Graphics and Modelling*** 2015, 56, 91–102.

99. Oleuropein potently inhibits mammalian target of rapamycin: possible involvement of tandem anomeric hyperconjugation–Michael reaction. **MO Taha**, MA Khanfar. ***Medicinal Chemistry Research*** 2015, 24, 616-623.

100. Tryptophan and thiosemicarbazide derivatives: design, synthesis, and biological evaluation as potential β-d-galactosidase and β-d-glucosidase inhibitors. RA Khalaf, AM Abdula, MS Mubarak, **MO Taha**. ***Medicinal Chemistry Research***. 2015. Paper In Press.

101. Ritodrine inhibits neuronal nitric oxide synthase, a potential link between tocolysis and autism. GARY Suaifan, MB Shehadeh, HAN Al-Ijel, KT Al-Jamal, **MO Taha**. ***Medicinal Chemistry Research***. 2014, 23, 5102-5109.

Propriety Rights: Patents and Copyrights

1) **Software Copyrights**: A 3D Multiconformer Virtual Structure Database of established drugs and agrochemicals. Mutasem O. Taha. 2008.

2) **Software Copyrights**: Binding Interactions Locator - Docking-based Comparative Intermolecular Contacts Analysis (dbCICA). Khaled Younis and Mutasem O Taha. 2008.

3) **Software Copyrights**: QSARtool – Acccess to Nonlinear Quantitative Structure-Activity Relationship Analyses. Khaled Younis and Mutasem O Taha. 2008.

4) **Patent**: Aptamers as Jak2 Kinase Inhibitors, Reg. No. 2535, Amman-Jordan, Reg. Date: 9-December-2011, Said Ismail**; Mutasem Taha**; Walhan Alshaer.

5) **Patent**: Thujon corrects cholesterol and triglycerides profiles in diabtetic rats. Reg. No. 2614, Amman-Jordan, Reg. Date 21-2-2012. Ahmad Dessi, Nore Haj-Baddar, Talal Aburjai, **Mutasem O. Taha**

6) **Software Copyrights** A flexible, digital, three-dimensional structural database suitable for *in-silico* screening that include 30,000 natural compounds isolated from east-mediteranian flora. Registered within the Jordanian Ministry of Trade and Industry.

7) **Patent**: Use of phenobarbital for the treatment of wounds. Reg. No. 2620, Amman-Jordan, Reg. Date 21-2-2012. Disi, Ahmad; Ajwee, Dema; **Taha, Mutasem**; Qunaibi, Eyad.

8) **Patent** : use of ethosuximide for the treatment of wounds. Reg. No. 2619, Amman-Jordan, Reg. Date 21-2-2012. **Taha, Mutasem**; Ajwee, Dema; Disi, Ahmad; Qunaibi, Eyad.

Prizes and Awards

1. Loughborough University Chemistry Department Award for Distinction in the M.Sc. Program (**1994**).
2. A two-month DAAD-sponsered research award at the Institute of Pharmacy/Hamburg University (Germany) in collaboration with Prof. Geffken (**2002**).
3. The Jordan University Prize for Distinguished Research Projects in **2004-2005** for the paper entitled: "Ligand-Based Assessment of Factor Xa Binding Site Flexibility via Elaborate Pharmacophore Exploration and Genetic Algorithm-Based QSAR Modeling." Published in the ***European Journal of Medicinal Chemistry***, 2005, 40(7), 701-727.
4. The Prize of The Jordanian Ministry of Higher Education for Distinguished Research Projects in **2008** for the paper entitled: "Effects of variable docking conditions and scoring functions on the qualities of protein aligned CoMFA models constructed from diverse h-PTP 1B inhibitors. Mutasem O. Taha*, Murad AlDhamin. ***Journal of Medicinal Chemistry***. 2005, 48, 8016-8034."
5. An-Najah Research Award for the year 2009 for the paper entitled: "Combining Ligand-Based Pharmacophore Modeling, QSAR Analysis and In -Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors. Mutasem O. Taha*, Lina A. Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suheer Saleh. ***Journal of Medicinal Chemistry***, 2008, 51, 6478–6494."
6. University of Jordan Prize for Research Distinction during the Academic Year **2008/2009**

7. The Prize of The Jordanian Scientific Research Support Fund for Distinguished Research Projects in Medical and Pharmaceutical Fields during the year **2011** for the paper entitled: "Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies. ***Journal Chemical Information and modelling***, 2011, 51 (3), pp 647–669
8. Ali Hamdi Mango Award for Distinguished Researchers at the University of Jordan for the year **2011**.
9. University of Jordan Prize for Research Distinction during the Academic Year 2010/2011
10. Applied Sciences Private University Certificate for Distinguished Researchers during the Academic Year **2011-2012**.
11. Daniel Turnberg Travel Fellowship Award-Academy of Medical Sciences-United Kingdom. September **2012**.

Scientific and Professional memberships

- Currently member of the editorial board of the international journal ISRN Biomathematics.
- Served as Editor-in-Chief: of the Jordan Journal of Pharmaceutical Sciences during 2011 and 2012.
- Served as regional Editor of the Internet Chemistry Journal "**Molecules**" during 1996-2006.

Referees

- Professor Dr. H. Heaney, Chemistry Department, Loughborough University, Leics. UK

Email: H.Heaney@Lboro.ac.uk.

- Professor Dr. F. Afifi, Department of Pharmacetical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan. E-mail: afifi@ju.edu.jo.

- Professor Yusef Al-Abed, Center for Molecular Innovation, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, United States. Email: YAlAbed@NSHS.edu